Clinical trial
Comparative Atorvastatin Pleiotropic Effects
NCT00163202 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry · Completed
Key facts
| NCT number | NCT00163202 |
|---|---|
| Title | Comparative Atorvastatin Pleiotropic Effects |
| Official title | A Multicenter, Randomized Double-Blind Study Comparing The Pleiotropic Effects Of Atorvastatin 10 Mg And 80 Mg Over A 26-Week Period In Subjects With Coronary Atherosclerosis |
| Acronym | CAP |
| Lead sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry |
| Collaborators | MDS Pharma Services Industry Bio-Inova Life Sciences International |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Coronary Arteriosclerosis, Hypercholesterolemia |
| Intervention type | Drug, Procedure |
| Interventions | Blood samples, Atorvastatin |
| Enrollment | 330 |
| Start date | Jun 1, 2002 |
| Completion | Aug 1, 2005 |
| First posted | Sep 13, 2005 |
| Last update posted | Feb 18, 2021 |
| Countries | Canada, Czechia, France, Poland, Romania, Russia, Slovakia |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: